Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver, metabolic, and inflammatory diseases. Founded in 2000 and headquartered in Israel, the company operates within the healthcare and biotechnology sector, with a strong emphasis on addressing conditions that currently have li... mited treatment options. Galmed’s lead drug candidate is Aramchol, a first-in-class synthetic fatty acid–bile acid conjugate designed to target liver diseases, particularly non-alcoholic steatohepatitis (NASH) and fibrosis. This oral therapy is currently being evaluated in advanced clinical trials, including Phase III studies, highlighting its potential as a novel treatment for patients with metabolic disorders linked to obesity and diabetes. In addition to Aramchol, the company is developing other pipeline products such as Amilo-5MER, a synthetic peptide aimed at treating inflammatory conditions, and MyBiotics, which is in preclinical development for liver-related diseases. Galmed also collaborates with academic institutions and industry partners to expand its research capabilities and accelerate drug development.Read More